Healthcare provider profile · identity verified

Mohammad Mohiddin, M.D.

Internal Medicine · BELLINGHAM, WA · NPI 1609225077

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	590	179
Amlodipine Besylate	Amlodipine Besylate	384	112
Levothyroxine Sodium	Levothyroxine Sodium	343	79
Losartan Potassium	Losartan Potassium	249	85
Lisinopril	Lisinopril	245	78
Metformin Hcl	Metformin Hcl	243	64
Omeprazole	Omeprazole	231	72
Tamsulosin Hcl	Tamsulosin Hcl	222	72
Pravastatin Sodium	Pravastatin Sodium	208	48
Sertraline Hcl	Sertraline Hcl	192	52
Rosuvastatin Calcium	Rosuvastatin Calcium	188	58
Gabapentin	Gabapentin	172	61
Hydrochlorothiazide	Hydrochlorothiazide	159	59
Alendronate Sodium	Alendronate Sodium	158	42
Metoprolol Succinate	Metoprolol Succinate	149	51
Trazodone Hcl	Trazodone Hcl	130	38
Pantoprazole Sodium	Pantoprazole Sodium	126	34
Eliquis	Apixaban	102	22
Simvastatin	Simvastatin	94	28
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	92	21
Jardiance	Empagliflozin	91	31
Bupropion Xl	Bupropion Hcl	87	22
Ozempic	Semaglutide	83	17
Potassium Chloride	Potassium Chloride	83	22
Furosemide	Furosemide	81	25
Zolpidem Tartrate	Zolpidem Tartrate	79	21
Duloxetine Hcl	Duloxetine Hcl	75	22
Allopurinol	Allopurinol	73	23
Finasteride	Finasteride	73	20
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	67	58
Metoprolol Tartrate	Metoprolol Tartrate	61	22
Oxycodone Hcl	Oxycodone Hcl	61	28
Donepezil Hcl	Donepezil Hcl	60	suppressed
Ezetimibe	Ezetimibe	60	17
Mirtazapine	Mirtazapine	59	21
Alprazolam	Alprazolam	56	16
Escitalopram Oxalate	Escitalopram Oxalate	56	16
Citalopram Hbr	Citalopram Hydrobromide	54	17
Carvedilol	Carvedilol	53	21
Spironolactone	Spironolactone	53	15
Buspirone Hcl	Buspirone Hcl	51	15
Clopidogrel	Clopidogrel Bisulfate	49	16
Fluticasone Propionate	Fluticasone Propionate	49	26
Metformin Hcl Er	Metformin Hcl	48	21
Prednisone	Prednisone	46	20
Albuterol Sulfate Hfa	Albuterol Sulfate	41	33
Atenolol	Atenolol	40	12
Ropinirole Hcl	Ropinirole Hcl	40	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	39	suppressed
Acyclovir	Acyclovir	38	11
Clonazepam	Clonazepam	36	suppressed
Tramadol Hcl	Tramadol Hcl	36	22
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	35	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	35	28
Hydralazine Hcl	Hydralazine Hcl	34	suppressed
Montelukast Sodium	Montelukast Sodium	33	suppressed
Methocarbamol	Methocarbamol	32	suppressed
Pregabalin	Pregabalin	32	suppressed
Xarelto	Rivaroxaban	32	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	31	15
Fluoxetine Hcl	Fluoxetine Hcl	31	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	29	14
Azithromycin	Azithromycin	28	28
Isosorbide Mononitrate Er	Isosorbide Mononitrate	28	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	28	suppressed
Spiriva Handihaler	Tiotropium Bromide	27	suppressed
Estradiol	Estradiol	26	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	26	suppressed
Nifedipine Er	Nifedipine	26	suppressed
Symbicort	Budesonide/Formoterol Fumarate	26	suppressed
Warfarin Sodium	Warfarin Sodium	26	suppressed
Testosterone Cypionate	Testosterone Cypionate	24	suppressed
Ciclopirox	Ciclopirox	23	12
Valsartan	Valsartan	23	suppressed
Cephalexin	Cephalexin	22	17
Propranolol Hcl	Propranolol Hcl	22	suppressed
Doxycycline Monohydrate	Doxycycline Monohydrate	21	17
Famotidine	Famotidine	21	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	21	suppressed
Memantine Hcl	Memantine Hcl	20	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	19	suppressed
Glipizide	Glipizide	19	suppressed
Ipratropium Bromide	Ipratropium Bromide	19	suppressed
Lorazepam	Lorazepam	19	suppressed
Lovastatin	Lovastatin	19	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	18	suppressed
Januvia	Sitagliptin Phosphate	18	suppressed
Levetiracetam	Levetiracetam	18	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	18	suppressed
Armour Thyroid	Thyroid,pork	17	suppressed
Chlorthalidone	Chlorthalidone	17	suppressed
Dextroamphetamine-Amphetamine	Dextroamphetamine/Amphetamine	17	suppressed
Diazepam	Diazepam	17	suppressed
Ondansetron Hcl	Ondansetron Hcl	17	14
Ramipril	Ramipril	17	suppressed
Celecoxib	Celecoxib	16	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	16	suppressed
Paxlovid	Nirmatrelvir/Ritonavir	16	16
Tradjenta	Linagliptin	16	suppressed
Venlafaxine Hcl	Venlafaxine Hcl	16	suppressed
Hydroxychloroquine Sulfate	Hydroxychloroquine Sulfate	15	suppressed
Ranolazine Er	Ranolazine	15	suppressed
Fluconazole	Fluconazole	14	suppressed
Irbesartan	Irbesartan	14	suppressed
Methenamine Hippurate	Methenamine Hippurate	14	suppressed
Midodrine Hcl	Midodrine Hcl	14	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	14	suppressed
Tizanidine Hcl	Tizanidine Hcl	14	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	14	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	14	suppressed
Torsemide	Torsemide	13	suppressed
Benazepril Hcl	Benazepril Hcl	12	suppressed
Cefpodoxime Proxetil	Cefpodoxime Proxetil	12	12
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	12	suppressed
Otezla	Apremilast	12	suppressed
Repatha Sureclick	Evolocumab	12	suppressed
Valacyclovir	Valacyclovir Hcl	12	suppressed
Acetaminophen-Codeine	Acetaminophen With Codeine	11	suppressed
Dabigatran Etexilate	Dabigatran Etexilate Mesylate	11	suppressed
Glipizide Er	Glipizide	11	suppressed
Testosterone	Testosterone	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error